tirzepatide for mcas Retatrutide vs. Tirzepatide: The Next-Gen GLP-1 Showdown mcas and tirzepatide Can GLP-1

To address this, Australian health authorities have approved temporary access to semaglutide products registered overseas, but these alternatives are not covered by PBS subsidies

Households with GLP-1 users could account for 35% of food and beverage sales by 2030, up from 23% today, per Circana

Each formulations dosing and titration schedule is distinct, so patients should never substitute one for another without medical supervision

Lau DC, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, et al

For broader regulatory context, see FDA Peptide Reclassification 2026: What It Means for Canadian Researchers